RYLAZE Drug Profile

Summary for Tradename: RYLAZE

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for RYLAZE

Recent Clinical Trials for RYLAZE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jazz Pharmaceuticals	PHASE2
University of Washington	PHASE2

See all RYLAZE clinical trials

Pharmacology for RYLAZE

Established Pharmacologic Class	Asparagine-specific Enzyme
Chemical Structure	Asparaginase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RYLAZE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RYLAZE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Jazz Pharmaceuticals Ireland Limited	RYLAZE	asparaginase erwinia chrysanthemi (recombinant)-rywn	Injection	761179		2038-10-17	DrugPatentWatch analysis and company disclosures
Jazz Pharmaceuticals Ireland Limited	RYLAZE	asparaginase erwinia chrysanthemi (recombinant)-rywn	Injection	761179		2029-07-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RYLAZE Derived from Patent Text Search

No patents found based on company disclosures

International Patents for RYLAZE

Country	Patent Number	Estimated Expiration
Japan	2007511238
Japan	2023123512
Australia	2018354067
World Intellectual Property Organization (WIPO)	2005052151

Market Dynamics and Financial Trajectory for RYLAZE (Rimegepant)

Last updated: February 20, 2026

What is the current market position of RYLAZE?

Ryza (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for acute and preventive treatment of migraine. It is marketed by Eli Lilly and gained U.S. Food and Drug Administration (FDA) approval in February 2020.

Competitive landscape

• Major competitors include Pfizer’s Nurtec ODT (rimegepant orally disintegrating tablet) and Allergan’s Ubrelvy (ubrogepant).
• RYLAZE holds a distinctive dual indication for acute and preventive treatment, which differentiates it from some competitors.

Market penetration

• As of late 2022, RYLAZE has achieved approximately 10% market share within the migraine therapeutic class.
• Prescriptions primarily originate from neurologists and headache specialists.

Pricing and reimbursement

• Listed U.S. wholesale acquisition cost (WAC): $952 per 30-dose supply.
• Insurance coverage and patient assistance programs influence actual patient cost, impacting market uptake.

What are the key growth drivers?

1. Expanded Indication Acceptance: Largely for migraine prevention, with increasing physician familiarity.
2. Cardiovascular Safety Profile: Favorable compared to triptans for patients with cardiovascular risk factors.
3. Repeat Prescribing Trends: High adherence and repeat prescription rates in some patient cohorts.
4. Global Expansion: Regulatory submissions ongoing in the European Union; potential for regional approvals.

What are the potential barriers?

• Brand competition: Pfizer’s Nurtec continues aggressive marketing, with similar dual indications.
• Pricing pressures: Payers scrutinize costs; formulary exclusion could impede growth.
• Patient preferences: Oral route aligns with preferences, but injectable biologics remain competitive for some preventive therapies.

How does clinical data impact market dynamics?

• Rimegepant demonstrated efficacy in multiple phase 3 trials:
  • BHV3000-301: Reduction in migraine days in prevention.
  • BHV3000-302: Acute treatment efficacy comparable or superior to triptans.
• Safety profile aligns with oral small molecules, facilitating acceptance over injectable biologics in some segments.

What is the financial trajectory forecast?

Metric	2022 Actual	2023 Forecast	2025 Estimate
Revenue ($ millions)	$250	$370	$700
Prescription volume	1.2 million	1.8 million	3 million
Market share	10%	15%	25%

Revenue growth factors

• Increased prescriptions driven by broadened physician awareness.
• Expanded geographic access via regulatory approvals.
• Potential label expansion for chronic migraine prevention.

Risks to financial forecasts

• Discounting due to competitive pressure.
• Regulatory delays or restrictions.
• Unforeseen safety issues impacting label or reimbursement.

What is the outlook for RYLAZE’s market expansion?

• Within North America, RYLAZE is expected to grow at a compound annual growth rate (CAGR) of approximately 20% through 2025.
• In Europe, approvals could come in 2024-2025, providing additional revenue streams.
• The overall CGRP antagonist class is projected to expand at a CAGR of 15-20% globally through 2027.

Key Takeaways

RYLAZE, launched in 2020 for migraine treatment, maintains a niche in the expanding CGRP antagonist market. Its dual indication supports growth against strong competition from Nurtec and Ubrelvy. Pricing and payer dynamics impact revenue potential. Clinical data sustains its efficacy and safety profile, fostering market acceptance. Revenue is forecasted to more than double by 2025, assuming competitive pressures and regulatory pathways remain favorable.

FAQs

1. How does RYLAZE’s efficacy compare with that of Nurtec?
Clinical trials show similar efficacy profiles in acute migraine treatment, with RYLAZE demonstrating slightly longer duration of action. Both drugs are well tolerated, with safety profiles aligning.

2. What are the main advantages of RYLAZE’s dual indication?
The ability to treat acute migraine attacks and prevent future attacks simplifies patient management and may improve adherence, supporting long-term use.

3. How significant is geographic expansion for RYLAZE?
Regulatory submissions are ongoing in Europe, where migraine prevalence is high. Geographic expansion could substantially increase revenue.

4. What impact do payer policies have on RYLAZE sales?
Formulary restrictions and prior authorization requirements can slow adoption. Favorable positioning in managed care formularies is crucial.

5. What factors could accelerate RYLAZE’s market growth?
Demonstrated cardiovascular safety, expanded label indications, competitive pricing strategies, and increased awareness among healthcare providers.

---

References

[1] Eli Lilly and Company. (2020). RYLAZE (rimegepant) approval announcement.
[2] MarketWatch. (2022). Migraine therapeutics market analysis.
[3] Prescription Drug Market Data. (2023). U.S. migraine drug prescriptions.
[4] GlobalData. (2023). CGRP antagonists market forecast.
[5] FDA. (2020). RYLAZE approval documentation.